Randomized, placebo-controlled trial of the effects of drospirenone- estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide

Menopause

Volumn 14, Issue 3, 2007, Pages 408-414

  Preston, Richard A ^a   Norris, Paul M ^a   Alonso, Alberto B ^a   Ni, Pingping ^b   Hanes, Vladimir ^b   Karara, Adel H ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

Aldosterone; Aldosterone antagonists; Diuretics; Drospirenone; Drug interactions; Hormone therapy; Hydrochlorothiazide; Hypertension; Potassium; Progesterone; Progestogens

Indexed keywords

ALDOSTERONE ANTAGONIST; ANDROSTANE DERIVATIVE; ANTIHYPERTENSIVE AGENT; DROSPIRENONE; HYDROCHLOROTHIAZIDE; POTASSIUM;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MIDDLE AGED; POSTMENOPAUSE; POTASSIUM; TREATMENT OUTCOME;

EID: 33847011697     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/01.gme.0000243572.63322.f7     Document Type: Article

References (39)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988/2000. JAMA 2003;290:199-206.
2. Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part I: estimates of blood pressure levels. J Hypertens 2006;24:413-422.
3. Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006;24:423-430.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
5. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
6. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
7. Chalmers J, Todd A, Chapman N, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003;21:651-663.
8. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004;43:900-921.
9. Gierach GL, Johnson BD, Bairey Merz CN, et al. Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol 2006;47(3 Suppl):S50-S58.
10. Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol 2004;44:1636-1640.
11. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004;43:918-923.
12. Oelkers W. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-1821.
13. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
14. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-251.
15. Oelkers W. Effects of estrogens and progestogens on the reninaldosterone system and blood pressure. Steroids 1996;61:166-171.
16. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995;761:311-335.
17. Norman P, Castaner J, Castaner RM. Drospirenone. Drugs Future 2000;25:1247-1256.
18. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-727.
19. Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-A estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15:816-822.
20. Preston RA, White WB, Pitt B, et al. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804.
21. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17-β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-1984.
22. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-A-estradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246-253.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
24. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 2006;17:25-29.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
26. Schriffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47:312-318.
27. Farquiharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-597.
28. Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic dysfunction in essential hypertension. Hypertension 2002;40:647-652.
29. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
30. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34.
31. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
32. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92:38-42.
33. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006;1:256-262.
34. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
35. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
36. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
37. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
38. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al, for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 2003;289:2673-2684.
39. Steiner AZ, Hodis HN, Lobo RA, Shoupe D, Xiang M, Mack WJ. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive women: the Estrogen in the Prevention of Atherosclerosis Trial. Menopause 2005;12:728-733.